Failure of d-cycloserine to reverse cognitive disruption induced by scopolamine or phencyclidine in primates.
The partial glycine agonist d-cycloserine may be of therapeutic use as a cognitive enhancer. We examined the ability of d-cycloserine (3-14 mg/kg i.m.) to reverse cognitive impairments induced by scopolamine (0.03 mg/kg) or PCP (0.25 mg/kg). There was no evidence for a dose-related improvement in visuospatial memory using retention intervals of 2,10 or 20 sec. A possible explanation for these findings is that central glycine function cannot be adequately increased using systemic administration of d-cycloserine in this dose range.
Rupniak
N M
NM
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K.
Duchnowski
M
M
Tye
S J
SJ
Cook
G
G
Iversen
S D
SD
D000818:Animals; D003523:Cycloserine / Q000008:administration & dosage / Q000494:pharmacology*; D008253:Macaca mulatta; D008297:Male; D008568:Memory / Q000187:drug effects*; D010622:Phencyclidine / Q000494:pharmacology*; D011897:Random Allocation; D012601:Scopolamine / Q000494:pharmacology*
D003523:Cycloserine; D012601:Scopolamine; D010622:Phencyclidine